

**DR. REDDY'S LABORATORIES LTD.**

8-2-337, Road No. 3, Banjara Hills,  
Hyderabad - 500034. Telangana, India.

**CONTACT****INVESTOR RELATIONS**

SAUNAK SAVLA  
[saunaks@drreddys.com](mailto:saunaks@drreddys.com)  
(Ph: +91-40-49002135)

**MEDIA RELATIONS**

CALVIN PRINTER  
[calvinprinter@drreddys.com](mailto:calvinprinter@drreddys.com)  
(Ph: +91-40- 49002121)

## Dr. Reddy's Laboratories announces the launch of Resof Total in India

Hyderabad, India, 15 May 2017

For Immediate Release

Hyderabad, India, 15 May 2017: Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched the generic version of Sofosbuvir 400mg and Velpatasvir 100mg fixed dose combination, indicated for the treatment of Chronic Hepatitis C, under a brand name Resof Total, in India.

Dr. Reddy's Resof Total tablets are available in bottle count size of 28.

Resof Total is used for the treatment of adult patients with Chronic Hepatitis C Virus, Genotype 1,2,3,4,5 or 6 infection

- Without Cirrhosis or with compensated cirrhosis
- With decompensated cirrhosis for use in combination with Ribavirin

The Sofosbuvir 400mg and Velpatasvir 100mg fixed dose combination is a generic version of Gilead's brand Epclusa. Treatment with this combination achieves a cure rate of more than 90% in all genotypes of Hepatitis C virus (1,2,3,4, or 6). Achievement of higher cure rate with this combination in Hepatitis C genotype 3 addresses a significant unmet need, since infection with genotype 3 of Hepatitis C is upto 70% in Indian patients infected with Hepatitis C.

**About Dr. Reddy's:** Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: [www.drreddys.com](http://www.drreddys.com)

**Disclaimer:** This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues.

The company assumes no obligation to update any information contained herein.